Letter: Biological Therapies for Prurigo Nodularis in Systemic Disease

Abstract

Get full access to this article

View all access options for this article.

References

Yosipovitch

, Mollanazar

, Ständer

, et al. Dupilumab in patients with prurigo nodularis: Two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med. 2023; 29(5):1180–1190; doi: 10.1038/s41591-023-02320-9

Müller

, Zeidler

, Ständer

. Chronic prurigo including prurigo nodularis: New insights and treatments. Am J Clin Dermatol. 2024; 25(1):15–33; doi: 10.1007/s40257-023-00818-z

Dupixent. Prescribing Information. Sanofi and Regeneron Pharmaceuticals, Inc.; 2025.

Nemluvio. Prescribing Information. Galderma Laboratories, L.P.; 2024.

Huang

, Williams

, Kwatra

. Prurigo nodularis: Epidemiology and clinical features. J Am Acad Dermatol. 2020; 83(6):1559–1565; doi: 10.1016/j.jaad.2020.04.183